Tavapadon in Early Parkinson’s Disease: Promising Phase 3 Trial Highlights Safety and Motor Symptom Benefits
The phase 3 TEMPO-2 trial demonstrates that flexible-dose tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improves motor symptoms in early Parkinson's disease with a manageable safety profile, warranting further long-term study.